Article
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.
Cancer investigation - 1 May 2014
Ascierto Paolo Antonio, Simeone Ester, Sileni Vanna Chiarion, Del Vecchio Michele, Marchetti Paolo, Cappellini Gian Carlo Antonini, Ridolfi Ruggero, de Rosa Francesco, Cognetti Francesco, Ferraresi Virginia, Testori Alessandro, Queirolo Paola, Bernengo Maria Grazia, Guida Michele, Galli Luca, Mandalà Mario, Cimminiello Carolina, Rinaldi Gaetana, Carnevale-Schianca Fabrizio, Maio Michele
Abstract excerpt
Of 93 patients with pretreated, BRAF(V600) mutation-positive advanced melanoma who received vemurafenib or dabrafenib before (n = 45) or after (n = 48) treatment with ipilimumab 3 mg/kg, median overall survival (mOS) from first treatment was 9.9 and 14.5 months, respectively. Among patients treated with a BRAF inhibitor first, mOS from the end of BRAF inhibition was 1.2 months for those who did not complete...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.